drugset / Trial / NCT03662035
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to determine the efficacy and safety of apatinib combined with S-1 on advanced pancreatic cancer patients after failure of first-line chemotherapy.
Timeline
- Start
- 2018-09-15
- Primary completion
- 2020-03-01
- Completion
- 2020-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |